miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1

miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1
复制标题

miR-145通过调节多药耐药相关蛋白1使胆囊癌对顺铂敏感

DOI:
10.1007/s13277-016-4957-6
复制
发表时间:
2016-02
期刊:
影响因子:
--
通讯作者:
Wang J
Wang J
中科院分区:
--
文献类型:
--
作者:
Zhan Ming;Zhao Xiaonan;Wang Hui;Chen Wei;Xu Sunwang;Wang Wei;Shen Hui;Huang Shuai;Wang J

文献摘要

参考文献

相似文献

胆囊癌是胆道最常见的恶性肿瘤,预后较差。由于其高耐药性,全身化疗治疗GBC患者的成功率有限。MicroRNAs (miRNAs)是一种新兴的化学耐药调控因子,可调节耐药相关基因的表达。在这项研究中,我们通过体内和体外分析研究了miR-145表达与顺铂敏感性之间的关系。定量PCR (q-PCR)分析显示miR-145在GBC组织中的表达增加。此外,对GBC细胞系的研究表明,miR-145过表达会增加顺铂的疗效,而miR-145表达降低会降低顺铂的敏感性。此外,我们发现miR-145通过直接靶向mrp1mrna的3 ' -UTR加速了mrp1mrna的降解,因此增加了GBC细胞中的顺铂毒性。此外,较低的miR-145和较高的mrp1表达水平预示着接受化疗的GBC患者预后不良。总之,我们的研究结果为使用miR-145表达作为识别顺铂耐药GBC患者的生物标志物建立了理论基础,并提出了增加miR-145表达的治疗策略可能是GBC患者的一种新的治疗方法。
Gallbladder cancer (GBC) is the most common malignancy in biliary tract with poor prognosis. Due to its high chemoresistance, systemic chemotherapies have had limited success in treating GBC patients. MicroRNAs (miRNAs) are emerging novel regulators of chemoresistance, which modulate the expression of drug resistance-related genes. In this study, we investigated the association between miR-145 expression and cisplatin sensitivity by both in vivo and in vitro analysis. Quantitative PCR (q-PCR) analysis indicated an increased miR-145 expression in GBC tissues. In addition, studies on GBC cell lines suggested an increased cisplatin efficacy with miR-145 overexpression, whereas decreasing miR-145 expression reduced cisplatin sensitivity. Further, we found that miR-145 acceleratedMRP1mRNA degradation by directly targeting its 3′-UTR and therefore caused increased cisplatin toxicity in GBC cells. Moreover, lower miR-145 and higherMRP1expression levels predicted poor prognosis in GBC patients who received chemotherapy. Collectively, our findings established a rationale for using miR-145 expression as a biomarker to identify cisplatin-resistant GBC patients and propose that treatment strategies increasing the expression of miR-145 could be a new therapeutic approach for GBC patients.
DOI: 10.1158/2159-8290.cd-15-0854
发表时间: 2016-02
期刊: Cancer discovery
影响因子: 28.2
作者:
Dimitrova N;Gocheva V;Bhutkar A;Resnick R;Jong RM;Miller KM;Bendor J;Jacks T
通讯作者: Jacks T
DOI: 10.1158/0008-5472.can-10-2010
发表时间: 2010-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Bader AG;Brown D;Winkler M
通讯作者: Winkler M
DOI: 10.1073/pnas.1421365112
发表时间: 2015-04-07
影响因子: 11.1
作者:
Srivastava, Amit Kumar;Han, Chunhua;Wang, Qi-En
通讯作者: Wang, Qi-En
DOI: 10.3892/ijo.2014.2360
发表时间: 2014-06-01
影响因子: 5.2
作者:
Zhou, Huading;Guo, Weijie;Ma, Baojin
通讯作者: Ma, Baojin
DOI: 10.1038/ncb2769
发表时间: 2013-06
影响因子: 21.3
作者:
Pencheva N;Tavazoie SF
通讯作者: Tavazoie SF